
Eli Lilly and Company LLY
$ 1 277.31
-0.56%
Eli Lilly and Company ROCE Ratio | LLY
Annual ROCE Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 21.04 | 19.32 | 14.51 | 13.92 | 13.14 | 12.82 | 21.07 | 19.28 | 25.55 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.55 | 12.82 | 17.85 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Jaguar Health
JAGX
|
245.65 | $ 2.36 | 15.44 % | $ 5.5 M | ||
|
Protalix BioTherapeutics
PLX
|
-9.85 | $ 2.49 | -2.35 % | $ 196 M | ||
|
uniQure N.V.
QURE
|
-24.32 | $ 21.65 | -3.5 % | $ 1.24 B | ||
|
Stoke Therapeutics
STOK
|
-5.71 | $ 25.41 | 1.48 % | $ 1.5 B | ||
|
Xencor
XNCR
|
-27.93 | $ 29.2 | 15.95 % | $ 2.17 B | ||
|
Annexon
ANNX
|
-102.25 | $ 3.71 | -1.2 % | $ 575 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 1.71 | -4.21 % | $ 2.82 M | ||
|
Incyte Corporation
INCY
|
29.32 | $ 113.3 | -2.08 % | $ 22.1 B | ||
|
Mesoblast Limited
MESO
|
-13.2 | $ 12.43 | 1.22 % | $ 15 B | ||
|
MeiraGTx Holdings plc
MGTX
|
1829.24 | $ 9.2 | -0.16 % | $ 740 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
22.36 | $ 516.39 | -1.44 % | $ 132 B | ||
|
Burford Capital Limited
BUR
|
9.48 | $ 3.24 | -3.72 % | $ 710 M | ||
|
Catalyst Biosciences
CBIO
|
10.83 | $ 12.77 | -0.39 % | $ 1.14 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 25.47 | 1.29 % | $ 1.19 B | ||
|
Anika Therapeutics
ANIK
|
-7.7 | $ 21.19 | -1.07 % | $ 304 M | ||
|
Editas Medicine
EDIT
|
-586.37 | $ 2.4 | 0.05 % | $ 213 M | ||
|
Evogene Ltd.
EVGN
|
-84.53 | $ 0.37 | 0.44 % | $ 2.91 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
-79.52 | $ 0.36 | -10.09 % | $ 26.4 K | ||
|
Fortress Biotech
FBIO
|
-140.8 | $ 1.87 | -3.11 % | $ 52.2 M | ||
|
Fennec Pharmaceuticals
FENC
|
-10.46 | $ 10.12 | 0.4 % | $ 289 M | ||
|
Foghorn Therapeutics
FHTX
|
79.62 | $ 2.04 | 2.0 % | $ 128 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
19.81 | $ 13.76 | 4.13 % | $ 11.5 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 9.91 | 0.71 % | $ 271 M | ||
|
Sanofi
SNY
|
6.44 | $ 41.77 | 0.41 % | $ 51 B | ||
|
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 31.74 | 1.73 % | $ 4.04 B | ||
|
Geron Corporation
GERN
|
-30.36 | $ 1.15 | 2.23 % | $ 767 M | ||
|
Gossamer Bio
GOSS
|
139.07 | $ 9.2 | -4.27 % | $ 2.1 B | ||
|
Titan Pharmaceuticals
TTNP
|
-186.76 | - | -3.76 % | $ 3.47 M | ||
|
Allena Pharmaceuticals
ALNA
|
-53.64 | - | 3.16 % | $ 1.9 M | ||
|
ALX Oncology Holdings
ALXO
|
-400.37 | $ 1.14 | -2.56 % | $ 61.2 M | ||
|
Heron Therapeutics
HRTX
|
-17.71 | $ 0.3 | -0.46 % | $ 50 M | ||
|
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.55 | 0.85 % | $ 286 M | ||
|
TCR2 Therapeutics
TCRR
|
-108.97 | - | - | $ 58.1 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
5.72 | $ 17.02 | 0.98 % | $ 2.29 B | ||
|
iBio
IBIO
|
-41.0 | $ 0.71 | -1.28 % | $ 73.9 M | ||
|
ImmuCell Corporation
ICCC
|
4.28 | $ 10.21 | -0.37 % | $ 92.2 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Inhibikase Therapeutics
IKT
|
-30.06 | $ 1.51 | -5.03 % | $ 148 M | ||
|
Immunome
IMNM
|
-35.33 | $ 17.89 | -0.54 % | $ 1.56 B | ||
|
TFF Pharmaceuticals
TFFP
|
-228.86 | - | -60.05 % | $ 125 K | ||
|
InMed Pharmaceuticals
INM
|
-65.74 | $ 1.57 | 9.03 % | $ 6.54 M | ||
|
Inovio Pharmaceuticals
INO
|
-360.31 | $ 0.88 | -1.82 % | $ 41.3 M | ||
|
Innoviva
INVA
|
13.96 | $ 21.06 | 1.91 % | $ 1.42 B | ||
|
Iovance Biotherapeutics
IOVA
|
-52.06 | $ 13.78 | -2.24 % | $ 4.92 M | ||
|
Theratechnologies
THTX
|
-30.84 | - | - | $ 83.9 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-580.3 | - | -15.15 % | $ 60.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-13.43 | - | - | $ 521 M | ||
|
Axon Enterprise
AXON
|
-1.91 | $ 424.81 | 1.06 % | $ 33.2 B | ||
|
Axcella Health
AXLA
|
-1848.9 | - | -16.42 % | $ 249 M | ||
|
Keros Therapeutics
KROS
|
22.29 | $ 11.35 | 0.62 % | $ 422 M |